CORONAVIRUS

Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity

Sarah Sanchez¹, Nicole Palacio¹, Tanushree Dangi¹, Thomas Ciucci^{2,3}, Pablo Penaloza-MacMaster^{*1}

¹Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. ²David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY 14642, USA. ³Department of Microbiology and Immunology, Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY 14642, USA.

* Correspondence: Pablo Penaloza-MacMaster (ppm@northwestern.edu)

SARS-CoV-2 has caused a global pandemic that has infected more than 230 million people worldwide. Although several vaccine candidates have received emergency use authorization (EUA), there is still limited knowledge on how vaccine dosing affects immune responses. We performed mechanistic studies in mice to understand how the priming dose of an adenovirus-based SARS-CoV-2 vaccine affects long-term immunity to SARS-CoV-2. We first primed C57BL/6 mice with an adenovirus serotype 5 vaccine encoding the SARS-CoV-2 spike protein, similar to that used in the CanSino and Sputnik V vaccines. The vaccine prime was administered either at a standard dose or 1000-fold lower dose, followed by a boost with the standard dose four weeks later. Initially, the low dose prime induced lower immune responses relative to the standard dose prime. However, the low dose prime elicited immune responses that were qualitatively superior, and upon boosting, exhibited significantly more potent recall and functional capacity. We also report similar effects with a simian immunodeficiency virus (SIV) vaccine. These findings show an unexpected advantage of fractionating vaccine prime doses, warranting a re-evaluation of vaccine trial protocols for SARS-CoV-2 and other pathogens.

INTRODUCTION

Adenoviruses are widely used in vaccine research due to their high insert capacity and robust immunogenicity (1). In particular, adenovirus serotype 5 (Ad5) is among the most immunogenic vaccine vectors available, but over the last decade its clinical use has been hampered by its high seroprevalence in the human population (2–4). Recently, the COVID-19 pandemic has re-invigorated the clinical use of this widely characterized vector as a vaccine platform for preventing COVID-19.

Vaccines based on Ad5, such as the CanSino vaccine and the Sputnik V vaccine, as well as vaccines based on adenovirus serotype 26 (Ad26) and chimpanzee adenovirus (ChAdOx1), have been used in millions of people worldwide and have shown potent protection against severe COVID-19 disease (5–7). However, there are current attempts to enhance the overall magnitude and durability of immune responses, for example by altering vaccine dosing and boosting regimens. Optimization of prime-boost regimens may obviate the need for “third boosters,” which are now recommended for people over 65 years old, as well as patients at high risk of severe illness, including immunosuppressed individuals (8, 9). Importantly, the waning of immunity several months post-vaccination is associated with increase in the number of breakthrough infections (10), leading experts to consider additional boosters for the general population.

Before licensure, the clinical testing of vaccine candidates consists of three phases aimed at evaluating safety, immunogenicity and efficacy. In particular, phase I typically involves dose-escalation studies comparing a range of vaccine doses in people who receive the same dose of the vaccine during the prime and the boost. However, vaccine trials do not typically evaluate “intra-group dose escalation”, in which individuals would first receive a prime with a low dose and then a boost with a higher dose. Here, we performed studies in mice to determine the immunological effects of intra-group dose escalation. We first primed mice with a low dose or a standard dose of an Ad5-based COVID-19 vaccine, followed by homologous boosting with a standard dose to measure anamnestic immune responses. Our data show that limiting the priming dose of Ad5-vectored vaccines improves the boosting capacity of CD8⁺ T cell responses and antibody responses. This beneficial effect of limiting the priming dose was associated with reduced generation of vector-specific immune responses, as well as cell-intrinsic differences in memory T cell differentiation.

RESULTS

Low dose Ad5-based SARS-CoV-2 vaccine prime elicits T cells with high anamnestic capacity.

We first primed C57BL/6 mice intramuscularly with an Ad5 adenovirus vector expressing SARS-CoV-2 spike protein

(Ad5-SARS-CoV-2 spike (*I1*)), either at a low dose (**LD**) (**10⁶ PFU**) or a standard dose (**SD**) (**10⁹ PFU**). After four weeks, mice were boosted with the standard dose and CD8⁺ T cell responses were analyzed by MHC tetramer binding assays (Fig. 1A). We tracked a CD8⁺ T cell response against an epitope (VNFNFNGL) that is highly conserved in bat and SARS-like coronaviruses, including SARS-CoV-1, SARS-CoV-2, RatG13, HKU3, WIV1, WIV16, RsSHC014, Rs3367, Shaanxi2011, Rm1/2004, YN2018B, SC2018, HuB2013, GX2013, and BM48-31/BGR/2008/Yunnan2011, among other coronaviruses. We will refer to this conserved CD8⁺ T cell response as SARS-CoV-2-specific response, or K^b VL8 for simplicity, where V represents the first amino acid, L represents the last amino acid, and 8 represents the number of amino acids in the peptide sequence.

Initially, priming with a LD resulted in lower SARS-CoV-2-specific CD8⁺ T cell responses, relative to priming with a SD (Fig. 1B). This result is consistent with the well-reported observation that immunogenicity following adenovirus vaccination is dose-dependent (*12, 13*). However, an unexpected effect was observed after the booster immunization four weeks later. Mice that were initially primed with a LD exhibited significantly greater CD8⁺ T cell expansion upon boosting relative to mice that were initially primed with the higher SD (Fig. 1B-1E).

SARS-CoV-2-specific CD8⁺ T cells induced by the LD/SD regimen exhibited enhanced IFN γ expression based on in vitro stimulation of splenocytes with overlapping SARS-CoV-2 peptide pools at day 14 post-boost (Fig. 2A-2B). Moreover, there was a pattern of improved CD4⁺ T cell responses in the LD/SD regimen relative to the SD/SD regimen (Fig. 2C). We did not observe differences in CD4⁺ T cell subset differentiation (fig. S1). SARS-CoV-2-specific CD8⁺ T cells induced by the LD/SD regimen showed more robust granzyme B and Ki67 expression relative to the SD/SD regimen (Fig. 2D-2F), suggesting enhanced cytotoxicity and proliferation upon boosting. Collectively, these results demonstrate that limiting the priming dose of Ad5-SARS-CoV-2 spike elicits SARS-CoV-2-specific T cell responses with superior anamnestic and functional capacity.

Effects of vaccine dose on T cell phenotype.

The data above suggested qualitative differences in T cell responses following a single injection with either a low or a standard dose of vaccine based on the functional differences observed after boosting with a standard dose. It is known that after an initial antigen encounter, T cells differentiate into distinct subsets, including effector cells (Teff), effector memory cells (Tem), and central memory cells (Tcm). Teff and Tem subsets exhibit rapid cytotoxicity but tend to be more short-lived than Tcm. Conversely, the Tcm subset exhibits superior recall capacity (*14–16*). To evaluate if the priming dose affected the differentiation of these T cells subsets,

we immunophenotyped SARS-CoV-2-specific CD8⁺ T cells at week 4 post-prime. Primary CD8⁺ T cell responses generated by a LD prime exhibited more pronounced central memory markers, such as CD62L and CD127 (Fig. 3A-3D). In addition, CD8⁺ T cells induced by a LD prime showed higher levels of the CD44 activation marker (Fig. 3E) and lower levels of the inhibitory PD-1 receptor (Fig. 3F) and Tim-3 receptor (Fig. 3G), relative to CD8⁺ T cells induced after a SD prime. We also FACS-sorted SARS-CoV-2-specific CD8⁺ T cells at week 4 post-vaccination (prime only) and performed single-cell RNA-sequencing (scRNA-seq). SARS-CoV-2-specific CD8⁺ T cells elicited by a LD and a SD clustered separately, suggesting distinct transcriptional signatures (fig. S2A). CD8⁺ T cells elicited by a LD prime showed lower transcription of genes associated with effector and terminal differentiation, and higher transcription of genes associated with long-lived memory T cells (fig. S2B-S2C; Data file S1-S2). We also interrogated whether these effects on T cell differentiation could be due to distinct TCR usage by performing single-cell T cell receptor (TCR)-seq on SARS-CoV-2-specific CD8⁺ T cells at week 4 post-prime. In both LD and SD, TCR usage was biased for V β 11 (encoded by *TRBV16* gene) (fig. S2D-S2E), suggesting that the prime dose did not substantially affect TCR usage. Taken together, our functional data, phenotypic data, and transcriptomics data show that the strength of an initial antigen encounter has profound long-term effects on T cell differentiation following SARS-CoV-2 vaccination in mice.

Pre-existing immunity to adenoviral vectors can negatively affect vaccine-elicited immunity. We reasoned that since mice primed with a SD initially display a stronger virus-specific immune responses, this may result in more stringent competition for antigen during a subsequent booster immunization, impinging upon SARS-CoV-2-specific recall responses. To rule out the potential effects of pre-existing T cell-mediated immunity, we evaluated recall CD8⁺ T cells in the absence of other pre-existing responses, by performing adoptive transfers of low numbers of purified SARS-CoV-2-specific CD8⁺ T cells into naïve hosts. Four weeks after priming mice with a LD or a SD, we FACS-purified splenic SARS-CoV-2-specific CD8⁺ T cells (K^b VL8⁺) and transferred these at low numbers (500 cells) into congenically distinct naïve mice. One day after adoptive transfer, all recipient mice were vaccinated with the same SD (10⁹ PFU) of the vaccine, and secondary CD8⁺ T cell expansion was assessed by flow cytometry (Fig. 4A). We show that donor CD8⁺ T cells from mice that were primed with a LD exhibited more robust secondary expansion compared to those primed with a SD (Fig. 4B-4D). These data show that a “gentle” antigenic prime elicits CD8⁺ T cells that are intrinsically superior on a per-cell basis and better able to mount a secondary response upon a booster immunization. Our adoptive transfer experiment with normalized numbers of CD8⁺ T cells was also consistent with our

earlier phenotypic analyses showing that a LD prime preferentially elicits highly anamnestic Tcm rather than Tem cells.

LD/SD elicits superior SARS-CoV-2-specific antibody responses relative to SD/SD.

Our analyses so far have been focused on T cell responses, but we also report profound differences in antibody responses. After a single prime immunization, the LD elicited antibody responses that were expectedly lower compared to the SD. However, antibody responses elicited by the LD expanded more robustly upon boosting, resulting in a 6-fold increase in SARS-CoV-2 spike-specific IgG by 6 weeks after the initial prime dose (Fig. 5A). The LD/SD regimen resulted in a 2-fold increase in germinal center (GC) B cells upon boosting (week 6) relative to the SD/SD regimen (Fig. 5B-5C). Generation of GC B cells after SARS-CoV-2 vaccination is associated with induction of a SARS-CoV-2-neutralizing antibody response (17). Therefore, we performed neutralization assays using SARS-CoV-2 pseudovirus to measure the ability of vaccine-elicited antibodies to block initial viral entry. Consistent with the increase in GC B cells, the LD/SD regimen elicited a 72-fold improvement in neutralizing antibodies compared to SD/SD (Fig. 5D).

A current concern is that SARS-CoV-1 may re-enter the human population in the future, and it is currently unknown whether SARS-CoV-2 vaccines could confer cross-protection against SARS-CoV-1. We interrogated whether changing the priming dose of our SARS-CoV-2 vaccine could affect immune cross-reactivity to SARS-CoV-1. To answer this question, we measured antibody responses that bound to the original SARS-CoV-1 that was first identified in 2003. The LD/SD regimen resulted in a 9-fold increase in SARS-CoV-1-binding antibody responses relative to the SD/SD regimen (Fig. 5E). Altogether, these findings demonstrate that cross-reactive antibody responses to SARS-CoV-1 are also significantly enhanced when the initial priming dose is reduced.

Effects of extending the prime-boost interval and narrowing the priming dose.

A prior clinical trial with an adenovirus-based vaccine (AstraZeneca ChAdoX1) showed that a lower prime dose was associated with enhanced protection against SARS-CoV-2 (18). However, it was unclear if the prime-boost interval could have also played a role. Our studies above did not rule out potential effects by the prime-boost interval, so we performed additional experiments to examine the effect of a protracted prime-boost interval. We observed improved antibody responses with more protracted prime-boost intervals (fig. S3), suggesting that the prime-boost interval could also influence vaccine-elicited immunity.

Our studies have compared immune responses elicited by two distinct priming doses that were 1000-fold apart (10^6 versus 10^9 PFU). We then interrogated whether a similar pattern could be observed with a narrower range of priming doses

that were only 10-fold apart (10^6 , 10^7 , 10^8 PFU, with all mice receiving the same boosting dose of 10^8 PFU). These dose-escalation studies also showed a pattern of enhanced secondary responses in mice that received lower priming doses, but the differences were only statistically significant for antibodies when the doses were at least 100-fold apart (fig. S4). These data suggest that recall immune responses are inversely proportional to the priming dose, within the dose range tested.

Effects of priming dose on vector-specific responses.

Since the studies above were focused on transgene-specific responses, we next evaluated vector-specific responses. The LD prime elicited substantially lowered vector (Ad5 hexon)-specific antibody responses relative to the SD prime (fig. S5). Even after boost, mice that were initially primed with a LD elicited lower Ad5 hexon-specific antibody responses. This result shows that the improvement of humoral immune responses in the LD/SD regimen is specific to transgene-specific responses.

Pre-existing Ad5-specific humoral immunity accelerates transgene clearance.

Prior studies, in particular the HIV-1 STEP trial, have suggested that pre-existing immunity to viral vectors may be detrimental for vector-based vaccines (3). However, the exact mechanism by which pre-existing anti-vector immunity impairs vaccine efficacy is not fully understood. A prevailing wisdom is that pre-existing antibodies neutralize Ad5, precluding entry into host cells (19–22). However, it is not clear whether Ad5-specific antibodies (which we observed were more highly induced by a SD prime) can play a more critical role via antibody effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC). We interrogated these two possibilities by transferring naïve or Ad5-immune sera into naïve mice (via intraperitoneal injection), followed by immunization with a luciferase-expressing Ad5 vector 24 hours later. Luciferase expression was evaluated longitudinally by injecting mice intraperitoneally with luciferin, followed by in vivo luciferase quantification using IVIS, as performed previously (23). This model allowed visualization of both initial transduction of the vector (breakthrough virus) and long-term transgene expression by in vivo luminescence (Fig. 6A). Ad5-specific humoral responses did not appear to abrogate the initial entry of Ad5 into muscle cells; transgene expression was comparable in the two groups during the hyperacute phase (≤ 6 hours post-vaccination) (Fig. 6B-6C). However, Ad5-specific humoral responses quickly mitigated transgene expression after 24 hours post-vaccination. These data suggest that Ad5-specific antibodies may not fully prevent the entry of Ad5 into cells. Instead, Ad5-specific antibodies seem to play a more critical role in accelerating the clearance of Ad5-transduced cells at the site of vaccination, subsequently limiting transgene expression likely due to antibody effector mechanisms.

During a booster immunization, both secondary and primary (de novo) T cell responses contribute to the effector response (24, 25). Since pre-existing immunity to Ad5 downmodulates transgene expression following Ad5 immunization, we hypothesized that a LD prime would facilitate the future re-utilization of Ad5, by promoting antigen presentation and subsequent priming of immune responses. To test this, we primed mice with a LD or a SD of Ad5-SARS-CoV-2 spike. After 3 weeks, we boosted these mice with an Ad5 vector expressing a mismatched antigen (Ad5-OVA), and then measured primary (OVA-specific) CD8⁺ T cells (fig. S6A). Importantly, mice that were initially primed with a LD of Ad5-SARS-CoV-2 spike generated more primary (OVA-specific) CD8⁺ T cells in draining lymph nodes, after the Ad5-OVA boost (fig. S6B-6D). Altogether, our results indicate that a LD prime not only elicits memory T cells with enhanced recall capacity, but it also facilitates de novo priming of T cells, following subsequent reutilization of Ad5 vector expressing an unrelated antigen.

The studies above using Ad5-SARS-CoV-2 spike and Ad5-OVA vaccines have shown that transgene-specific responses are enhanced when the priming dose is reduced. We interrogated whether similar effects could be observed with another antigen. We first primed mice with an Ad5 vector expressing simian immunodeficiency virus (SIV) Gag protein (Ad5-SIV), and then boosted mice after 4 weeks (fig. S7A). Consistent with our prior results, we observed a significant improvement of SIV-specific CD8⁺ T cell responses with the LD/SD regimen, relative to the SD/SD regimen (fig. S7B-S7C), showing that our observations generalize to other antigen systems. In conclusion, we show that limiting the priming dose of Ad5-based vaccines results in substantial improvement of adaptive immune responses after boosting in mice.

DISCUSSION

Adenovirus-based SARS-CoV-2 vaccines are currently being deployed in humans to prevent COVID-19, including the Johnson & Johnson's Janssen vaccine, AstraZeneca/Oxford vaccine, CanSino vaccine, and the Sputnik V vaccine. These vaccines have already been administered to millions of people, and have shown potent immunogenicity, safety, and efficacy against severe SARS-CoV-2 infection. The CanSino and Sputnik V vaccines specifically utilize Ad5, which is the same vector platform used in our studies. Ad5 is among the most well-studied vaccine vectors, due in part to its extraordinary immunogenicity (2, 26). Although SARS-CoV-2 vaccines prevent severe disease and death, they do not always confer durable sterilizing immunity, warranting the further optimization of current vaccine regimens.

Here, we show that fractionating the priming dose of an adenovirus-based SARS-CoV-2 vaccine confers an unexpected immunological benefit after boosting. Importantly, a possible trade-off of fractionating the priming dose is that it may

initially result in lower antigen-specific immune responses, which may render the host transiently more susceptible to infection, although this requires investigation. While it remains unclear what the minimum level of immune responses required to protect against severe COVID-19 is, a recent study demonstrated that even a low dose single-shot of an Ad26-based SARS-CoV-2 vaccine is sufficient to confer protection against severe disease in primates (27). Similarly, a single dose of a DNA-based SARS-CoV-2 vaccine, which is ~1000-fold less immunogenic than a LD single-shot of the Ad5-based vaccine, was able to protect macaques from a SARS-CoV-2 challenge (28). These prior papers suggest that low levels of immune responses are sufficient to protect against severe COVID-19 (at least during the short time frame when the vaccines were tested), which can explain the extraordinary success of multiple SARS-CoV-2 vaccines in the last year.

There are historical examples of vaccine dose fractionation, also known as dose-sparing, as a way to enable more people to get vaccinated. For instance, prior studies have shown that administering a fifth of the recommended dose of the yellow fever virus vaccine results in comparable immune responses relative to the recommended dose, without selection of escape variants (29). Similar results have been reported for influenza, measles, polio, and typhoid vaccines (30–32), which has led to discussions of whether SARS-CoV-2 vaccine doses should be fractionated to enable more people to get vaccinated. However, a counterargument against vaccine fractionation is that it may result in suboptimal immune protection (relative to standard dose) before the boost is administered.

What is the possible mechanistic basis for the improved recall response observed in the LD/SD regimen? First, we observed that a LD prime induced lower expression of inhibitory receptors and higher expression of central memory markers on CD8⁺ T cells relative to a SD prime. Second, anti-vector immunity was substantially lower after a LD prime relative to a SD prime. Lower anti-vector immunity may facilitate transgene expression and antigen presentation, as well as more de novo priming following a subsequent boost. Interestingly, Ad5-specific antibodies did not prevent Ad5 from entering muscle cells, but resulted in more rapid elimination of Ad5 after 24 hours, likely via effector mechanisms. Whether blocking effector functions (such as ADCC) can allow the re-utilization of Ad5 vectors, especially in the context of high pre-existing immunity, requires further investigation. Our data with a simian immunodeficiency virus (SIV) vaccine and an OVA vaccine suggest that our findings may also be useful to improve other Ad5-based vaccines. Nevertheless, it is unclear why only the transgene-specific response (but not the vector-specific response) was increased in the LD/SD regimen. The hexon is the most abundant adenovirus capsid protein and is considered to be the main target for adenovirus

neutralizing antibodies (33, 34). Future studies should determine if the improvement of recall responses in the LD primed mice is dependent on the level of antigen expression, and whether similar effects can be observed with other vector platforms different than Ad5.

Conceptually, our findings are counterintuitive to conventional wisdom because we show that when it comes to the immune system, sometimes “less is more.” Antigen is the first signal required for the activation of the adaptive immune system, but here we show an example where a lower amount of priming antigen results in superior recall response later during boosting. We also show that reducing the priming dose of a vaccine favors Tcm differentiation, which is characterized by high expression of the IL-7 receptor α chain (CD127) that promotes long-term T cell survival. Tcm CD8⁺ T cells also exhibit enhanced recall capacity (14), which may explain the improved secondary expansion that was observed in our LD/SD regimen.

The LD/SD regimen also induced superior antibody responses compared to the SD/SD regimen. Strikingly, the LD/SD regimen elicited a 72-fold improvement in the neutralizing antibody response, compared to the SD/SD regimen. In vitro antibody neutralization is directly correlated with in vivo protection against SARS-CoV-2 challenges (28), but we did not perform in vivo SARS-CoV-2 challenges to compare immune protection, because in our pilot studies in k18-ACE2 mice, even a single-shot of the Ad5-SARS-CoV-2 spike vaccine provided robust protection. Similar efficacy has been described after a single dose with other adenovirus-based SARS-CoV-2 vaccines (35–37). It is plausible that a LD/SD regimen may confer a protective advantage over a SD/SD regimen months or years after vaccination when responses wane, which might reduce the need for a third boost. The LD/SD regimen may also be useful in individuals who develop suboptimal immune responses to vaccines, or those who may benefit from having a higher level of immune responses. Moreover, reducing vaccine dose may result in fewer side effects or adverse events, since reactogenicity is directly proportional to vaccine dose (38–40). There are concerns that SARS-CoV-1 may re-enter the human population, and an important question is whether the current SARS-CoV-2 vaccines could cross-protect against SARS-CoV-1. We analyzed cross-reactive antibody (binding to SARS-CoV-1 spike), and we show that the LD/SD regimen resulted in higher cross-reactive antibody levels compared to the SD/SD regimen. Notably, the CD8⁺ T cell response that we measured in these studies was specific for a highly conserved epitope (VNFNFGNL) that is present across multiple coronaviruses, including SARS-CoV-2, SARS-CoV-1, RatG13, HKU3, and WIV1, among others. Altogether, the LD/SD regimen may be particularly effective in the context of universal coronavirus vaccines, because this regimen induces potent levels of cross-reactive antibody and

CD8⁺ T cell responses.

The extent to which our results generalize to humans has not been determined, but a recent clinical trial with an adenovirus-based SARS-CoV-2 vaccine (ChAdOx1, nCoV-19), in which the priming dose was unintentionally reduced to half, reported superior efficacy relative to standard dose (90% efficacy for LD/SD, versus 62% efficacy for SD/SD) (18). However, in those studies it was unclear whether the improvement in the LD/SD group was due to prolonging the prime-boost interval or due to the priming dose itself. Our results bring more clarity to this issue, as we show that the priming dose alone can have a substantial qualitative effect on immune responses in mice. Historically, phase 1 vaccine trials are designed to compare a range of vaccine doses among different groups of individuals. However, they do not typically analyze the effect of dose-escalation within the same individual. The data presented support exploring intra-group vaccine dose escalation in future clinical trials and may be useful to understand the immunological effects of vaccine fractionation.

MATERIALS AND METHODS

Study design

The goal of this study was to understand how an Ad5 prime dose affects T cell and antibody responses in mice. Mice were first immunized intramuscularly with a low dose versus a standard dose of an Ad5-based SARS-CoV-2 vaccine, and after several weeks they were all boosted with a standard dose. Blood was harvested at different timepoints to measure SARS-CoV-2 specific T cell responses in PBMCs, and SARS-CoV-2 specific and vector-specific antibody responses in sera. Neutralizing antibody responses were also assessed pre- and post-vaccination using luciferase-based SARS-CoV-2 pseudovirus assays.

Ad5-SARS-CoV-2 spike vaccine and other vaccines

The non-replicating Ad5 vector is E1/E3 deleted and expresses the SARS-CoV-2 spike protein (strain 2019-nCoV-WIV04) within the putative E1 site (11, 42). This vector contains a CMV (Cytomegalovirus) promoter driving the expression of SARS-CoV-2 spike protein. The Ad5-SIV, Ad5-OVA, and Ad5-luciferase vectors have a similar genetic makeup, but express their respective transgene in the putative E1 site, instead of spike. The Ad5-SARS-CoV-2 spike, Ad5-OVA, and Ad5-luciferase vectors were constructed and propagated at the Iowa Vector Core on trans-complementing HEK293 cells (ATCC), purified by cesium chloride density gradient centrifugation, titrated, and then frozen at -80°C . The Ad5-SIV (expressing Gag from SIVmac239) was obtained from Dr. John Mascola (NIH), and propagated in our laboratory as indicated above. The Ad5-OVA vector was originally developed by Dr. Thomas Griffith (University of Minnesota).

Mice and vaccinations

6-8-week-old C57BL/6 mice were used. Mice were

purchased from Jackson laboratories (approximately half males and half females). Mice were immunized intramuscularly (50 μ L per quadriceps) with an Ad5 vector expressing SARS-CoV-2 spike protein (Ad5-SARS-CoV-2 spike) or the indicated Ad5 vector diluted in sterile PBS. Mice were housed at the Northwestern University Center for Comparative Medicine (CCM) in downtown Chicago. All mouse experiments were performed with approval of the Northwestern University Institutional Animal Care and Use Committee (IACUC).

Reagents, flow cytometry, and equipment

Single cell suspensions were obtained from PBMCs and various tissues as described previously (43). Dead cells were gated out using Live/Dead fixable dead cell stain (Invitrogen). SARS-CoV-2 spike peptide pools used for intracellular cytokine staining (ICS) and these were obtained from BEI Resources. Biotinylated MHC class I monomers (K^b VL8, sequence VNFNFNGL), as well as the other tetramers used in this study, were obtained from the NIH tetramer facility at Emory University. The VNFNFNGL epitope is highly conserved among multiple coronaviruses, representing a cross-reactive CD8⁺ T cell response. It is located in position 539-546 of the SARS-CoV-2 spike protein, or position 525-532 of the SARS-CoV-1 spike protein. Cells were stained with fluorescently-labeled antibodies against CD8 α (53-6.7 on PerCP-Cy5.5), CD44 (IM7 on Pacific Blue), IFN γ (XMGL2 on APC), peanut agglutinin or PNA (conjugated to fluorescein), Fas (Jo2 on PE), IgD (11-26 on Pacific Blue), IgM (RMM-1 on PECy7), B220 (RA3-6B2 on PerCP-Cy5.5), CXCR5 (SPRCL5 conjugated to biotin and then to streptavidin-PE), Ly6C (HK1.4 on Pacific Blue), Granzyme B (GB11 on PE), Ki67 (B56 on FITC), CD107a (1D4B on FITC), CD45.1 (A20 on PE-Cy7), CD45.2 (104 on FITC), CD25 (PC61 on PerCP-Cy5.5), FoxP3 (FJK.16S on APC), IL-4 (BVD6-24G2 on PE-Cy7), CD4 (RM4-5 on FITC), CD3 (145-2c11 on FITC), Tim-3 (RMT3-23 on PE), PD-1 (RMPI-30 APC), CD62L (MEL-14 on PE-Cy7), and CD127 (A7R34 on FITC). CD4⁺ T cell subsets (e.g., Th1, Tfh, Treg) were identified following established phenotypes from prior papers (44–47). Fluorescently-labeled antibodies were purchased from BD Pharmingen, except for anti-CD44 (which was from Biolegend). Flow cytometry samples were acquired with a Becton Dickinson Canto II or an LSRII and analyzed using FlowJo (Treestar).

Ad5 hexon, homologous (SARS-CoV-2 spike) and heterologous (SARS-CoV-1 spike) virus-specific ELISA

Binding antibody titers were measured using ELISA as described previously (48–50), but using spike protein instead of viral lysates. In brief, 96-well flat bottom plates MaxiSorp (Thermo Scientific) were coated with 0.1 μ g/well of the respective spike protein, for 48 hours at 4°C. Plates were washed with PBS + 0.05% Tween-20. Blocking was performed for 4 hours at room temperature with 200 μ L of PBS + 0.05% Tween-20 + bovine serum albumin. 6 μ L of sera were added

to 144 μ L of blocking solution in first column of plate, 1:3 serial dilutions were performed until row 12 for each sample and plates were incubated for 60 min at room temperature. Plates were washed three times followed by addition of goat anti-mouse IgG horseradish peroxidase conjugated (Southern Biotech) diluted in blocking solution (1:5000), at 100 μ L/well and incubated for 60 min at room temperature. Plates were washed three times and 100 μ L/well of Sure Blue substrate (Sera Care) was added for approximately 8 min. Reaction was stopped using 100 μ L/well of KPL TMB stop solution (Sera Care). Absorbance was measured at 450 nm using a Spectra-max Plus 384 (Molecular Devices). Ad5 hexon protein was purchased from Abcam (ab123995). SARS-CoV-2 spike protein was made at the Northwestern Recombinant Protein Production Core by Dr. Sergii Pshenychnyi using a plasmid that was produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Vector pCAGGS containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Gene (soluble, stabilized), NR-52394. SARS-CoV-1 spike protein was obtained through BEI Resources, NIAID, NIH: SARS-CoV Spike (S) Protein deltaTM, Recombinant from Baculovirus, NR-722.

Pseudovirus neutralization assays

A SARS-CoV-2 Spike pseudotyped lentivirus kit was obtained through BEI Resources, NIAID, NIH (SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike-Pseudotyped Lentiviral Kit V2, NR-53816). We used Human Embryonic Kidney Cells (HEK-293T) expressing Human Angiotensin-Converting Enzyme 2, also known as HEK-293T-hACE2, which are susceptible to SARS-CoV-2. This cell line was obtained through BEI Resources, NIAID, NIH NR-52511. Serial dilutions of sera were incubated with the SARS-CoV-2 Spike pseudotyped lentivirus, following a protocol by Balazs and Bloom (51). Cells were lysed using luciferase cell culture lysis buffer (Promega). Luciferase reaction was performed using 30 μ L of cell lysis (Promega). The reaction was added to 96-well black optiplates (Perkin Elmer). Luminescence was measured using Perkin Elmer Victor³ luminometer.

Single cell RNA-Seq data acquisition and analysis

C57BL/6 mice were immunized with a LD (10^6 PFU) or a SD (10^9 PFU) of Ad5-SARS-CoV-2 spike, and at day 28, splenic CD8⁺ T cells were MACS-sorted with a MACS negative selection kit (STEMCELL). Purified CD8⁺ T cells were stained with K^b VL8 tetramer, live dead stain, and flow cytometry antibodies for CD8⁺ and CD44 to gate on activated CD8⁺ T cells. Live, CD8⁺, CD44⁺, K^b VL8⁺ cells were FACS-sorted to ~99% purity on a FACS Aria cytometer (BD Biosciences) and delivered to the Northwestern University NUSeq core for scRNA-seq using Chromium NextGem 5' v2 kit (10X Genomics). After the library was sequenced, the output file in BCL format was converted to fastq files and aligned to mouse genome in order to generate a matrix file using the Cell Ranger pipeline (10X

Genomics). These upstream QC steps were performed by Drs. Ching Man Wai and Matthew Schipma at the Northwestern University NUSeq core. Further analyses were performed in R using the Seurat package v4.0, as previously described (52). Terminal effector gene signatures were derived using the edgeR package (53), comparing effector memory to terminal effector CD8⁺ T cells (54). Clusters representing less than 4% of each population were excluded from downstream analyses. TCR analyses was performed using the scRepertoire package (55). Only cells expressing both TCRα and TCRβ chains were selected. For cells with more than 2 TCR chains, only the top 2 expressed chains were used.

Adoptive CD8⁺ T cell transfers

CD45.2⁺ C57BL/6 mice were immunized intramuscularly with a LD (10⁶ PFU) or a SD (10⁹ PFU) of Ad5-SARS-CoV-2 spike, and at day 28, splenic CD8⁺ T cells were enriched using MACS negative selection kit (STEMCELL). Purified CD8⁺ T cells were stained with K^b VL8 tetramer and live dead stain, and FACS-sorted to ~99% purity on a FACS Aria cytometer (BD Biosciences). Live K^b VL8 tetramer⁺ cells were transferred intravenously into naïve CD45.1 C57BL/6 mice intravenously (~500 cells per mouse). Recipient mice were vaccinated intramuscularly with a SD (10⁹ PFU) of Ad5-SARS-CoV-2 spike 24 hours later. PBMCs and spleens were harvested ~2 weeks post-boost for flow cytometric analyses.

In vivo bioluminescence

Sera from C57BL/6 mice immunized with 10⁹ PFU of Ad5-empty (week 4 post-immunization) or naïve C57BL/6 mice were collected. 1000 µL of immune or naïve sera were then transferred intraperitoneally into white (A/J) recipient mice. Recipient A/J mice were immunized intramuscularly with Ad5-luciferase (10⁹ PFU) 24 hours following sera transfer. Mice were imaged at various times post-immunization. To quantify luciferase expression, luciferin (Goldbio CAT# LUCK-100, 10 µL/g weight) was administered intraperitoneally 15 min prior to imaging, and mice were imaged for 2 min using a Kino IVIS Imager (Spectral Instruments Imaging). Region of interest (ROI) bioluminescence was used to quantify response.

Statistical analysis

Statistical tests used are indicated on each figure legend. Dashed lines in data figures represent limit of detection. Data were analyzed using Prism version 9 (Graphpad).

SUPPLEMENTARY MATERIALS

www.science.org/doi/10.1126/sciimmunol.abi8635

Figs. S1 to S7

Data files S1 to S3

REFERENCES AND NOTES

1. N. Tatsis, H. C. Ertl, Adenoviruses as vaccine vectors. *Mol. Ther.* **10**, 616–629 (2004). [doi:10.1016/j.ymthe.2004.07.013](https://doi.org/10.1016/j.ymthe.2004.07.013) [Medline](#)
2. Q. A. Alayo, N. M. Provine, P. Penaloza-MacMaster, Novel Concepts for HIV Vaccine Vector Design. *MSphere* **2** (2017). [doi:10.1128/mSphere.00415-17](https://doi.org/10.1128/mSphere.00415-17) [Medline](#)
3. S. P. Buchbinder, D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B.

- Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, M. N. Robertson; Step Study Protocol Team, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. *Lancet* **372**, 1881–1893 (2008). [doi:10.1016/S0140-6736\(08\)61591-3](https://doi.org/10.1016/S0140-6736(08)61591-3) [Medline](#)
4. D. H. Barouch, S. V. Kik, G. J. Weverling, R. Dilan, S. L. King, L. F. Maxfield, S. Clark, D. Ng'ang'a, K. L. Brandariz, P. Abbink, F. Sinangil, G. de Bruyn, G. E. Gray, S. Roux, L. G. Bekker, A. Dilraj, H. Kibuuka, M. L. Robb, N. L. Michael, O. Anzala, P. N. Amornkul, J. Gilmour, J. Hural, S. P. Buchbinder, M. S. Seaman, R. Dolin, L. R. Baden, A. Carville, K. G. Mansfield, M. G. Pau, J. Goudsmit, International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. *Vaccine* **29**, 5203–5209 (2011). [doi:10.1016/j.vaccine.2011.05.025](https://doi.org/10.1016/j.vaccine.2011.05.025) [Medline](#)
5. N. C. Kyriakidis, A. López-Cortés, E. V. González, A. B. Grimaldos, E. O. Prado, SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. *NPJ Vaccines* **6**, 28 (2021). [doi:10.1038/s41541-021-00292-w](https://doi.org/10.1038/s41541-021-00292-w) [Medline](#)
6. C. B. Creech, S. C. Walker, R. J. Samuels, SARS-CoV-2 Vaccines. *JAMA* **325**, 1318–1320 (2021). [doi:10.1001/jama.2021.3199](https://doi.org/10.1001/jama.2021.3199) [Medline](#)
7. K. Subbarao, The success of SARS-CoV-2 vaccines and challenges ahead. *Cell Host Microbe* **29**, 1111–1123 (2021). [doi:10.1016/j.chom.2021.06.016](https://doi.org/10.1016/j.chom.2021.06.016) [Medline](#)
8. V. G. Hall, V. H. Ferreira, T. Ku, M. Ierullo, B. Majchrzak-Kita, C. Chaparro, N. Selzner, J. Schiff, M. McDonald, G. Tomlinson, V. Kulasingam, D. Kumar, A. Humar, Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. *N. Engl. J. Med.* **385**, 1244–1246 (2021). [doi:10.1056/NEJMc2111462](https://doi.org/10.1056/NEJMc2111462) [Medline](#)
9. V. G. Hall, V. H. Ferreira, M. Ierullo, T. Ku, T. Marinelli, B. Majchrzak-Kita, A. Yousuf, V. Kulasingam, A. Humar, D. Kumar, Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. *Am. J. Transplant.* **ajt.16766** (2021). [doi:10.1111/ajt.16766](https://doi.org/10.1111/ajt.16766) [Medline](#)
10. M. Bergwerk, T. Gonen, Y. Lustig, S. Amit, M. Lipsitch, C. Cohen, M. Mandelboim, E. G. Levin, C. Rubin, V. Idenbaum, I. Tal, M. Zavitan, N. Zuckerman, A. Bar-Chaim, Y. Kreiss, G. Regev-Yochay, Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *N. Engl. J. Med.* **NEJMoa2109072** (2021). [doi:10.1056/NEJMoa2109072](https://doi.org/10.1056/NEJMoa2109072) [Medline](#)
11. T. Dangi, J. Class, N. Palacio, J. M. Richner, P. Penaloza MacMaster, Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. *Cell Rep.* **36**, 109664 (2021). [doi:10.1016/j.celrep.2021.109664](https://doi.org/10.1016/j.celrep.2021.109664) [Medline](#)
12. K. M. Quinn, D. E. Zak, A. Costa, A. Yamamoto, K. Kastenmuller, B. J. Hill, G. M. Lynn, P. A. Darrah, R. W. Lindsay, L. Wang, C. Cheng, A. Nicosia, A. Folgori, S. Colloca, R. Cortese, E. Gostick, D. A. Price, J. G. Gall, M. Roederer, A. Aderem, R. A. Seder, Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. *J. Clin. Invest.* **125**, 1129–1146 (2015). [doi:10.1172/JCI78280](https://doi.org/10.1172/JCI78280) [Medline](#)
13. E. A. Weaver, Dose Effects of Recombinant Adenovirus Immunization in Rodents. *Vaccines (Basel)* **7**, 144 (2019). [doi:10.3390/vaccines7040144](https://doi.org/10.3390/vaccines7040144) [Medline](#)
14. E. J. Wherry, V. Teichgräber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, R. Ahmed, Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nat. Immunol.* **4**, 225–234 (2003). [doi:10.1038/ni889](https://doi.org/10.1038/ni889) [Medline](#)
15. F. Sallusto, J. Geginat, A. Lanzavecchia, Central memory and effector memory T cell subsets: Function, generation, and maintenance. *Annu. Rev. Immunol.* **22**, 745–763 (2004). [doi:10.1146/annurev.immunol.22.012703.104702](https://doi.org/10.1146/annurev.immunol.22.012703.104702) [Medline](#)
16. J. Geginat, A. Lanzavecchia, F. Sallusto, Proliferation and differentiation potential of human CD8⁺ memory T-cell subsets in response to antigen or homeostatic cytokines. *Blood* **101**, 4260–4266 (2003). [doi:10.1182/blood-2002-11-3577](https://doi.org/10.1182/blood-2002-11-3577) [Medline](#)
17. K. Lederer, D. Castañó, D. Gómez Atria, T. H. Oguin 3rd, S. Wang, T. B. Manzoni, H. Muramatsu, M. J. Hogan, F. Amanat, P. Cherubin, K. A. Lundgreen, Y. K. Tam, S. H. Y. Fan, L. C. Eisenlohr, I. Maillard, D. Weissman, P. Bates, F. Krammer, G. D. Sempowski, N. Pardi, M. Locci, SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. *Immunity* **53**, 1281–1295.e5 (2020). [doi:10.1016/j.immuni.2020.11.009](https://doi.org/10.1016/j.immuni.2020.11.009) [Medline](#)
18. M. D. Knoll, C. Wonodi, Oxford-AstraZeneca COVID-19 vaccine efficacy. *Lancet* **397**, 72–74 (2021). [doi:10.1016/S0140-6736\(20\)32623-4](https://doi.org/10.1016/S0140-6736(20)32623-4) [Medline](#)
19. H. Gahéry-Ségard, F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, J. G. Guillet, Immune response to recombinant capsid proteins of

- adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. *J. Virol.* **72**, 2388–2397 (1998). [doi:10.1128/JVI.72.3.2388-2397.1998](https://doi.org/10.1128/JVI.72.3.2388-2397.1998) [Medline](#)
20. A. Kass-Eisler, L. Leinwand, J. Gall, B. Bloom, E. Falck-Pedersen, Circumventing the immune response to adenovirus-mediated gene therapy. *Gene Ther.* **3**, 154–162 (1996). [Medline](#)
 21. C. I. Toogood, J. Crompton, R. T. Hay, Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. *J. Gen. Virol.* **73**, 1429–1435 (1992). [doi:10.1099/0022-1317-73-6-1429](https://doi.org/10.1099/0022-1317-73-6-1429) [Medline](#)
 22. C. Wohlfart, Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms. *J. Virol.* **62**, 2321–2328 (1988). [doi:10.1128/jvi.62.7.2321-2328.1988](https://doi.org/10.1128/jvi.62.7.2321-2328.1988) [Medline](#)
 23. R. A. Larocca, N. M. Provine, M. Aid, M. J. Iampietro, E. N. Borducchi, A. Badamchi-Zadeh, P. Abbink, D. Ng'ang'a, C. A. Bricault, E. Blass, P. Penaloza-MacMaster, K. E. Stephenson, D. H. Barouch, Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4⁺ T cell responses that impair CD8⁺ T cell function. *Sci. Immunol.* **1**, eaaf7643 (2016). [doi:10.1126/sciimmunol.aaf7643](https://doi.org/10.1126/sciimmunol.aaf7643) [Medline](#)
 24. W. G. Tan, H. T. Jin, E. E. West, P. Penaloza-MacMaster, A. Wieland, M. J. Zilliox, M. J. McElrath, D. H. Barouch, R. Ahmed, Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8⁺ T cells induced by different adenovirus vectors. *J. Virol.* **87**, 1359–1372 (2013). [doi:10.1128/JVI.02055-12](https://doi.org/10.1128/JVI.02055-12) [Medline](#)
 25. P. Penaloza-MacMaster, J. E. Teigler, R. C. Obeng, Z. H. Kang, N. M. Provine, L. Parenteau, S. Blackmore, J. Ra, E. N. Borducchi, D. H. Barouch, Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens. *J. Virol.* **88**, 6243–6254 (2014). [doi:10.1128/JVI.00406-14](https://doi.org/10.1128/JVI.00406-14) [Medline](#)
 26. P. Penaloza-MacMaster, N. M. Provine, J. Ra, E. N. Borducchi, A. McNally, N. L. Simmons, M. J. Iampietro, D. H. Barouch, Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. *J. Virol.* **87**, 1373–1384 (2013). [doi:10.1128/JVI.02058-12](https://doi.org/10.1128/JVI.02058-12) [Medline](#)
 27. X. He, A. Chandrashekar, R. Zahn, F. Wegmann, J. Yu, N. B. Mercado, K. McMahan, A. J. Martinot, C. Piedra-Mora, S. Beecy, S. Ducat, R. Chamanza, S. R. Huber, L. van der Fits, E. N. Borducchi, M. Lifton, J. Liu, F. Nampanya, S. Patel, L. Peter, L. H. Tostanoski, L. Pessaint, A. Van Ry, B. Finneyfrock, J. Velasco, E. Teow, R. Brown, A. Cook, H. Andersen, M. G. Lewis, H. Schuitemaker, D. H. Barouch, Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques. *bioRxiv*, (2021).
 28. J. Yu, L. H. Tostanoski, L. Peter, N. B. Mercado, K. McMahan, S. H. Mahrokhian, J. P. Nkolola, J. Liu, Z. Li, A. Chandrashekar, D. R. Martinez, C. Loos, C. Atyeo, S. Fischinger, J. S. Burke, M. D. Sleyn, Y. Chen, A. Zuiani, F. J. N. Lelis, M. Travers, S. Habibi, L. Pessaint, A. Van Ry, K. Blade, R. Brown, A. Cook, B. Finneyfrock, A. Dodson, E. Teow, J. Velasco, R. Zahn, F. Wegmann, E. A. Bondzie, G. Dagotto, M. S. Gebre, X. He, C. Jacob-Dolan, M. Kirilova, N. Kordana, Z. Lin, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. D. Ventura, H. Wan, Y. Cai, B. Chen, A. G. Schmidt, D. R. Wesemann, R. S. Baric, G. Alter, H. Andersen, M. G. Lewis, D. H. Barouch, DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* **369**, 806–811 (2020). [doi:10.1126/science.abc6284](https://doi.org/10.1126/science.abc6284) [Medline](#)
 29. J. T. Wu, C. M. Peak, G. M. Leung, M. Lipsitch, Fractional dosing of yellow fever vaccine to extend supply: A modelling study. *Lancet* **388**, 2904–2911 (2016). [doi:10.1016/S0140-6736\(16\)31838-4](https://doi.org/10.1016/S0140-6736(16)31838-4) [Medline](#)
 30. S. Riley, J. T. Wu, G. M. Leung, Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. *PLOS Med.* **4**, e218 (2007). [doi:10.1371/journal.pmed.0040218](https://doi.org/10.1371/journal.pmed.0040218) [Medline](#)
 31. J. L. Schnyder, C. A. De Pijper, H. M. Garcia Garrido, J. G. Daams, A. Goorhuis, C. Stijnis, F. Schaumburg, M. P. Grobusch, Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. *Travel Med. Infect. Dis.* **37**, 101868 (2020). [doi:10.1016/j.tmaid.2020.101868](https://doi.org/10.1016/j.tmaid.2020.101868) [Medline](#)
 32. H. Okayasu, C. Sein, D. Chang Blanc, A. R. Gonzalez, D. Zehrung, C. Jarrahian, G. Macklin, R. W. Sutter, Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. *J. Infect. Dis.* **216** (suppl_1), S161–S167 (2017). [doi:10.1093/infdis/jix038](https://doi.org/10.1093/infdis/jix038) [Medline](#)
 33. H. Wu, I. Dmitriev, E. Kashentseva, T. Seki, M. Wang, D. T. Curiel, Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. *J. Virol.* **76**, 12775–12782 (2002). [doi:10.1128/JVI.76.24.12775-12782.2002](https://doi.org/10.1128/JVI.76.24.12775-12782.2002) [Medline](#)
 34. D. M. Roberts, A. Nanda, M. J. Havenga, P. Abbink, D. M. Lynch, B. A. Ewald, J. Liu, A. R. Thorner, P. E. Swanson, D. A. Gorgone, M. A. Lifton, A. A. Lemckert, L. Holterman, B. Chen, A. Dilraj, A. Carville, K. G. Mansfield, J. Goudsmit, D. H. Barouch, Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. *Nature* **441**, 239–243 (2006). [doi:10.1038/nature04721](https://doi.org/10.1038/nature04721) [Medline](#)
 35. A. O. Hassan, N. M. Kafai, I. P. Dmitriev, J. M. Fox, B. K. Smith, I. B. Harvey, R. E. Chen, E. S. Winkler, A. W. Wessel, J. B. Case, E. Kashentseva, B. T. McCune, A. L. Bailey, H. Zhao, L. A. VanBlargan, Y. N. Dai, M. Ma, L. J. Adams, S. Shrihari, J. E. Danis, L. E. Gralinski, Y. J. Hou, A. Schäfer, A. S. Kim, S. P. Keeler, D. Weiskopf, R. S. Baric, M. J. Holtzman, D. H. Fremont, D. T. Curiel, M. S. Diamond, A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* **183**, 169–184.e13 (2020). [doi:10.1016/j.cell.2020.08.026](https://doi.org/10.1016/j.cell.2020.08.026) [Medline](#)
 36. N. B. Mercado, R. Zahn, F. Wegmann, C. Loos, A. Chandrashekar, J. Yu, J. Liu, L. Peter, K. McMahan, L. H. Tostanoski, X. He, D. R. Martinez, L. Rutten, R. Bos, D. van Manen, J. Vellinga, J. Custers, J. P. Langedijk, T. Kwaks, M. J. G. Bakkers, D. Zuidgeest, S. K. Rosendahl Huber, C. Atyeo, S. Fischinger, J. S. Burke, J. Feldman, B. M. Hauser, T. M. Caradonna, E. A. Bondzie, G. Dagotto, M. S. Gebre, E. Hoffman, C. Jacob-Dolan, M. Kirilova, Z. Li, Z. Lin, S. H. Mahrokhian, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. P. Nkolola, S. Patel, J. D. Ventura, K. Verrington, H. Wan, L. Pessaint, A. Van Ry, K. Blade, A. Strasbaugh, M. Cabus, R. Brown, A. Cook, S. Zouantchangadou, E. Teow, H. Andersen, M. G. Lewis, Y. Cai, B. Chen, A. G. Schmidt, R. K. Reeves, R. S. Baric, D. A. Lauffenburger, G. Alter, P. Stoffels, M. Mammen, J. Van Hoof, H. Schuitemaker, D. H. Barouch, Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature* **586**, 583–588 (2020). [doi:10.1038/s41586-020-2607-z](https://doi.org/10.1038/s41586-020-2607-z) [Medline](#)
 37. S. Wu, G. Zhong, J. Zhang, L. Shuai, Z. Zhang, Z. Wen, B. Wang, Z. Zhao, X. Song, Y. Chen, R. Liu, L. Fu, J. Zhang, Q. Guo, C. Wang, Y. Yang, T. Fang, P. Lv, J. Wang, J. Xu, J. Li, C. Yu, L. Hou, Z. Bu, W. Chen, A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. *Nat. Commun.* **11**, 4081 (2020). [doi:10.1038/s41467-020-17972-1](https://doi.org/10.1038/s41467-020-17972-1) [Medline](#)
 38. J. Sadoff, M. Le Gars, G. Shukarev, D. Heerwegh, C. Truysers, A. M. de Groot, J. Stoop, S. Tete, W. Van Damme, I. Leroux-Roels, P. J. Berghmans, M. Kimmel, P. Van Damme, J. de Hoon, W. Smith, K. E. Stephenson, S. C. De Rosa, K. W. Cohen, M. J. McElrath, E. Cormier, G. Scheper, D. H. Barouch, J. Hendriks, F. Struyf, M. Douoguih, J. Van Hoof, H. Schuitemaker, Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *N. Engl. J. Med.* **384**, 1824–1835 (2021). [doi:10.1056/NEJMoa2034201](https://doi.org/10.1056/NEJMoa2034201) [Medline](#)
 39. M. N. Ramasamy, A. M. Minassian, K. J. Ewer, A. L. Flaxman, P. M. Folegatti, D. R. Owens, M. Voysey, P. K. Aley, B. Angus, G. Babbage, S. Belli-Rammerstorfer, L. Berry, S. Bibi, M. Bittaye, K. Cathie, H. Chappell, S. Charlton, P. Cicconi, E. A. Clutterbuck, R. Colin-Jones, C. Dold, K. R. W. Emary, S. Fedosyuk, M. Fuskova, D. Gbesemete, C. Green, B. Hallis, M. M. Hou, D. Jenkin, C. C. D. Joe, E. J. Kelly, S. Kerridge, A. M. Lawrie, A. Lelliott, M. N. Lwin, R. Makinson, N. G. Marchevsky, Y. Mujaididi, A. P. S. Munro, M. Pacurar, E. Plested, J. Rand, T. Rawlinson, S. Rhead, H. Robinson, A. J. Ritchie, A. L. Ross-Russell, S. Saich, N. Singh, C. C. Smith, M. D. Snape, R. Song, R. Tarrant, Y. Themistocleous, K. M. Thomas, T. L. Villafana, S. C. Warren, M. E. E. Watson, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, S. N. Faust, A. J. Pollard; Oxford COVID Vaccine Trial Group, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. *Lancet* **396**, 1979–1993 (2021). [doi:10.1016/S0140-6736\(20\)32466-1](https://doi.org/10.1016/S0140-6736(20)32466-1) [Medline](#)
 40. F. C. Zhu, Y. H. Li, X. H. Guan, L. H. Hou, W. J. Wang, J. X. Li, S. P. Wu, B. S. Wang, Z. Wang, L. Wang, S. Y. Jia, H. D. Jiang, L. Wang, T. Jiang, Y. Hu, J. B. Gou, S. B. Xu, J. J. Xu, X. W. Wang, W. Wang, W. Chen, Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet* **395**, 1845–1854 (2020). [doi:10.1016/S0140-6736\(20\)31208-3](https://doi.org/10.1016/S0140-6736(20)31208-3) [Medline](#)
 41. P. Penaloza-MacMaster, D. L. Barber, E. J. Wherry, N. M. Provine, J. E. Teigler, L. Parenteau, S. Blackmore, E. N. Borducchi, R. A. Larocca, K. B. Yates, H. Shen, W. N. Haining, R. Sommerstein, D. D. Pinschewer, R. Ahmed, D. H. Barouch, Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection.

- Science* **347**, 278–282 (2015). [doi:10.1126/science.aaa2148](https://doi.org/10.1126/science.aaa2148) [Medline](#)
42. L. Feng, Q. Wang, C. Shan, C. Yang, Y. Feng, J. Wu, X. Liu, Y. Zhou, R. Jiang, P. Hu, X. Liu, F. Zhang, P. Li, X. Niu, Y. Liu, X. Zheng, J. Luo, J. Sun, Y. Gu, B. Liu, Y. Xu, C. Li, W. Pan, J. Zhao, C. Ke, X. Chen, T. Xu, N. Zhong, S. Guan, Z. Yuan, L. Chen, An adenovirus-vectored COVID-19 vaccine confers protection from SARS-CoV-2 challenge in rhesus macaques. *Nat. Commun.* **11**, 4207 (2020). [doi:10.1038/s41467-020-18077-5](https://doi.org/10.1038/s41467-020-18077-5) [Medline](#)
 43. D. Masopust, V. Vezys, A. L. Marzo, L. Lefrançois, Preferential localization of effector memory cells in nonlymphoid tissue. *Science* **291**, 2413–2417 (2001). [doi:10.1126/science.1058867](https://doi.org/10.1126/science.1058867) [Medline](#)
 44. M. Bhattacharyya, P. Madden, N. Henning, S. Gregory, M. Aid, A. J. Martinot, D. H. Barouch, P. Penaloza-MacMaster, Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection. *Immunology* **152**, 328–343 (2017). [doi:10.1111/imm.12771](https://doi.org/10.1111/imm.12771) [Medline](#)
 45. J. S. Hale, B. Youngblood, D. R. Latner, A. U. Mohammed, L. Ye, R. S. Akondy, T. Wu, S. S. Iyer, R. Ahmed, Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. *Immunity* **38**, 805–817 (2013). [doi:10.1016/j.immuni.2013.02.020](https://doi.org/10.1016/j.immuni.2013.02.020) [Medline](#)
 46. P. Penaloza-MacMaster, A. O. Kamphorst, A. Wieland, K. Araki, S. S. Iyer, E. E. West, L. O'Mara, S. Yang, B. T. Konieczny, A. H. Sharpe, G. J. Freeman, A. Y. Rudensky, R. Ahmed, Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. *J. Exp. Med.* **211**, 1905–1918 (2014). [doi:10.1084/jem.20132577](https://doi.org/10.1084/jem.20132577) [Medline](#)
 47. S. S. Iyer, D. R. Latner, M. J. Zilliox, M. McCausland, R. S. Akondy, P. Penaloza-MacMaster, J. S. Hale, L. Ye, A. U. Mohammed, T. Yamaguchi, S. Sakaguchi, R. R. Amara, R. Ahmed, Identification of novel markers for mouse CD4(+) T follicular helper cells. *Eur. J. Immunol.* **43**, 3219–3232 (2013). [doi:10.1002/eji.201343469](https://doi.org/10.1002/eji.201343469) [Medline](#)
 48. T. Dang, Y. R. Chung, N. Palacio, P. Penaloza-MacMaster, Interrogating Adaptive Immunity Using LCMV. *Curr. Protoc. Immunol.* **130**, e99 (2020). [doi:10.1002/cpim.99](https://doi.org/10.1002/cpim.99) [Medline](#)
 49. N. Palacio, T. Dang, Y. R. Chung, Y. Wang, J. L. Loreda-Varela, Z. Zhang, P. Penaloza-MacMaster, Early type I IFN blockade improves the efficacy of viral vaccines. *J. Exp. Med.* **217**, e20191220 (2020). [doi:10.1084/jem.20191220](https://doi.org/10.1084/jem.20191220) [Medline](#)
 50. Y. Wang, Y. R. Chung, S. Eitzinger, N. Palacio, S. Gregory, M. Bhattacharyya, P. Penaloza-MacMaster, TLR4 signaling improves PD-1 blockade therapy during chronic viral infection. *PLOS Pathog.* **15**, e1007583 (2019). [doi:10.1371/journal.ppat.1007583](https://doi.org/10.1371/journal.ppat.1007583) [Medline](#)
 51. K. H. D. Crawford, R. Eguia, A. S. Dingens, A. N. Loes, K. D. Malone, C. R. Wolf, H. Y. Chu, M. A. Tortorici, D. Veasler, M. Murphy, D. Pettie, N. P. King, A. B. Balazs, J. D. Bloom, Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**, 513 (2020). [doi:10.3390/v12050513](https://doi.org/10.3390/v12050513) [Medline](#)
 52. T. Ciucci, M. S. Vacchio, Y. Gao, F. Tomassoni Ardori, J. Candia, M. Mehta, Y. Zhao, B. Tran, M. Pepper, L. Tassarollo, D. B. McGavern, R. Bosselut, The Emergence and Functional Fitness of Memory CD4+ T Cells Require the Transcription Factor Thpok. *Immunity* **50**, 91–105.e4 (2019). [doi:10.1016/j.immuni.2018.12.019](https://doi.org/10.1016/j.immuni.2018.12.019) [Medline](#)
 53. M. D. Robinson, D. J. McCarthy, G. K. Smyth, edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010). [doi:10.1093/bioinformatics/btp616](https://doi.org/10.1093/bioinformatics/btp616) [Medline](#)
 54. J. J. Milner, H. Nguyen, K. Omilusik, M. Reina-Campos, M. Tsai, C. Toma, A. Delpoux, B. S. Boland, S. M. Hedrick, J. T. Chang, A. W. Goldrath, Delineation of a molecularly distinct terminally differentiated memory CD8 T cell population. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 25667–25678 (2020). [doi:10.1073/pnas.2008571117](https://doi.org/10.1073/pnas.2008571117) [Medline](#)
 55. N. Borchering, N. L. Bormann, G. Kraus, scRepertoire: An R-based toolkit for single-cell immune receptor analysis. *F1000 Res.* **9**, 47 (2020). [doi:10.12688/f1000research.22139.2](https://doi.org/10.12688/f1000research.22139.2) [Medline](#)

Acknowledgments: We thank Drs. Susan Weiss, Stanley Perlman, and Thomas Gallagher for discussions. **FUNDING:** This work was possible with a grant from the Emerging and Re-Emerging Pathogens Program (EREPP) at Northwestern University, and a grant from the National Institute on Drug Abuse (NIDA,

DP2DA051912) to P.P.M. **AUTHOR CONTRIBUTIONS:** P.P.M., S.S., N.P., T.D., and T.C. designed and conducted the experiments. P.P.M. wrote the manuscript with feedback from all authors. **COMPETING INTERESTS:** Pablo Penaloza-MacMaster reports being Task Force Advisor to the Illinois Department of Public Health (IDPH) on SARS-CoV-2 vaccine approval and implementation in the state of Illinois. Pablo Penaloza-MacMaster is also member of the Northwestern COVID-19 Vaccine Communication and Evaluation Network (CoVAXCEN) at Northwestern University's Institute for Global Health. **DATA AND MATERIALS AVAILABILITY:** RNA and TCR sequencing data are available in the Gene Expression Omnibus under accession number GSE173567. All other data needed to evaluate the conclusions in the paper and present in the paper or the Supplementary Materials. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

Submitted 5 April 2021

Accepted 7 October 2021

Published First Release 14 October 2021

10.1126/sciimmunol.abi8635

Fig. 1. A low dose Ad5-SARS-CoV-2 spike vaccine prime elicits more SARS-CoV-2 CD8⁺ T cells after boosting compared to a standard dose prime. (A) Experimental approach for evaluating how the priming dose, either 10⁶ PFU (low dose, LD) or 10⁹ PFU (standard dose, SD) of an Ad5-SARS-CoV-2 spike vaccine affects CD8⁺ T cell responses after a SD boost 4 weeks later in C57BL/6 mice. (B) Representative FACS plots showing the frequencies of SARS-CoV-2-specific CD8⁺ T cells (K^b VL8⁺) in PBMCs. (C) Summary of SARS-CoV-2-specific CD8⁺ T cell responses in PBMCs. (D) Representative FACS plots showing the frequencies of SARS-CoV-2-specific CD8⁺ T cells (K^b VL8⁺) in spleen. (E) Summary of SARS-CoV-2-specific CD8⁺ T cell responses in spleen at day 14 post-boost. Data are from two experiments, one with n=5 mice per group, and another with n=4-5 mice per group. All data are shown. Indicated *P* value was determined by two-way ANOVA in (C); and by unpaired *t* test in (E). Error bars represent SEM.

Fig. 2. A LD/SD vaccine regimen elicits more functional CD8⁺ T cell responses compared to a SD/SD vaccine regimen. (A-C) Splenocytes were incubated with overlapping SARS-CoV-2 peptide pools for 5 hours at 37°C in the presence of GolgiStop and GolgiPlug to detect SARS-CoV-2-specific CD8⁺ and CD4⁺ T cell responses at day 14 post-boost. **(A)** Representative FACS plots showing the frequencies of SARS-CoV-2-specific CD8⁺ T cells expressing the degranulation marker CD107a. IFN γ ⁺ cells are overlaid in red and their frequencies are indicated in red. **(B)** Summary of SARS-CoV-2-specific CD8⁺ T cells that express IFN γ . **(C)** Summary of SARS-CoV-2-specific CD4⁺ T cells that express IFN γ . **(D)** Representative FACS plots showing the frequencies of granzyme B and Ki67 expressing CD8⁺ T cells in spleen (gated from K^b VL8⁺ cells). **(E)** Summary of Ki67 expression. **(F)** Summary of granzyme B expression. Data from (E-F) are indicated as mean fluorescence intensity (MFI). Data are from two experiments, one with n=5 per group, and another with n=4-5 per group. All data are shown (day 14 post-boost). Indicated *P* values were determined by parametric test (unpaired *t* test).

Fig. 3. Phenotype of CD8⁺ T cell responses after a single prime with the Ad5-SARS-CoV-2 spike vaccine. (A) Representative FACS plots showing the frequencies of peripheral blood SARS-CoV-2-specific CD8⁺ T cells (K^b VL8) that differentiate into effector memory and central memory T cell subsets. (B) Summary of effector (Teff), effector memory (Tem) and central memory (Tcm) T cell subsets. (C) CD127 expression. (D) CD62L expression. (E) CD44 expression. (F) PD-1 expression. (G) Tim-3 expression. Data are gated from SARS-CoV-2-specific CD8⁺ T cells (K^b VL8) from PBMCs. All data are from day 28 post-prime. Data are from one experiment with n=5 per group. Experiment was repeated with similar results, (see Data file S3). Indicated *P* values were determined by parametric test (unpaired *t* test).

Fig. 5. A LD/SD vaccine regimen elicits antibody responses with superior recall potential compared to a SD/SD vaccine regimen. Vaccination regimen was the same as Fig. 1A. **(A)** Summary of SARS-CoV-2-specific antibody responses in sera of mice treated with either a LD or SD prime dose and a SD boost dose 4 weeks later. **(B)** Representative FACS plots showing the frequencies of germinal center (GC) B cells in spleen. Cells were gated from $CD3^+ B220^+ IgM^- IgD^-$, as this gating strategy can be used to identify GC B cells (41). **(C)** Summary of GC B cells in spleen. (B-C) are from week 6. **(D)** Summary of SARS-CoV-2 neutralizing antibody responses in sera. **(E)** Summary of SARS-CoV-1-binding antibody responses in sera at week 5. Data are from two experiments, one with $n=5$ per group, and another with $n=4-5$ per group. All data are shown. In (D) (week 5), insufficient sera was obtained from one SD/SD mouse after boost, so the total number of replicates in this group is $n=8$. Indicated P value was determined by two-way ANOVA in (A); by parametric test (unpaired t test) in (C) and (E); and by two-way ANOVA (Dunnett's multiple comparisons test) in (D). Dashed line indicates limit of detection. Error bars represent SEM.

Fig. 6. Ad5-specific humoral responses limit the duration of transgene expression following Ad5 immunization. (A) Experimental approach for evaluating the effect of Ad5-specific humoral responses on transgene expression. Sera donors were Ad5-immune (week 4 post-immunization) or naïve C57BL/6 mice; and recipients were naïve A/J mice (with white coat) to allow for improved visualization of luciferase by in vivo bioluminescence. One day after passive immunization (1000 μ L sera/mouse intraperitoneally), recipient A/J mice were immunized intramuscularly with 10^9 PFU of Ad5-luciferase. (B) Summary of transgene expression by in vivo bioluminescence imaging. Each adjacent dot represents the luciferase signal from the left and right quadriceps (adjacent dots are from the same mouse). Each quadriceps represents an independent data point as it is a separate site of immunization. (C) Representative bioluminescence images. Data are from two experiments, one with $n=4-5$ per group, and another with $n=1$ per group. All data are shown. Indicated P value was determined by parametric test (unpaired t test).